Antibacterial properties of pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: Combined effects of MAb and ceftazidime

Microbiology and Immunology

Volumn 44, Issue 8, 2000, Pages 629-635

  Akiyama, Moritoshi ^a   Oishi, Kazunori ^a   Tao, Misao ^a   Matsumoto, Keizo ^a   Pollack, Matthew ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Ceftazidime; LPS; Monoclonal antibody; Pseudomonas aeruginosa; Thigh infection model

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LD3 2F2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPENIA; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CEFTAZIDIME; CEPHALOSPORINS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; LIPOPOLYSACCHARIDES; MICE; NEUTROPHILS; PHAGOCYTOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIGH;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0033850840     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2000.tb02543.x     Document Type: Article

References (26)

1. Enhanced phagocytosis, killing, and serum sensitivity of Escherichia coli and Staphylococcus aureus treated with sub-MICs of imipenem
2. Bacteremic nosocomial pneumonia
3. Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa
4. Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients
5. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice
6. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in vivo model
7. Hypersusceptibility of penicillin-treated gronp B streptococci to bacterial activity of human polymorphonuclear leukocytes
8. Bacteremic Pseudomonas pneumonia
9. Hospital-acquired gram-negative rod pneumonias: An overview
10. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonifis and thigh-infection models
11. Bactericidal effect of polymorphonuclear neutrophils on antibiotic-induced filaments of gram-negative bacilli
12. Postantibiotic leukocyte enhancement: Increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes
13. Influence of subinhibitory concentration of antibiotics on opsonization and phagocytosis of Pseudomonas aeruginosa by human polymorphonuclear leukocytes
14. Enhanced killing of group B streptococci in vitro by penicillin and opsonophagocytosis with intravenous immunoglobulin
15. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: Relation to antibody isotype and complement-fixing activity
16. Effects of the combination of lipopolysaccharide-specific monoclonal antibody and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice
17. Carumonam enhances reactivity of Escherichia coli with mono and polyclonal antisera to rough mutant Escherichia coli J5
18. Pseudomonas pneumonia. A retrospective study of 36 cases
19. Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host
20. Use of third-generation cephalosporins. Pseudomonas
21. Specificity and cross reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide
22. Enhanced susceptibility of gram-negative bacteria to phagocytic killing by human polymorphonuclear leucocytes after brief exposure to aztreonam
23. Pseudomonas aeruginosa infections: Persisting problems and current research to find new therapies
24. Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa
25. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
26. In vivo postantibiotic effect in a thigh infection in neutropenic mice